Business
Azitra, Inc. Announces Q1 2025 Results and Provides Business Updates
Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update.
About this update from Azitra Inc
[{"type":"text","content":"BRANFORD, Conn., May 13, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended March 31, 2025, and provided a business update.","length":302,"tagName":"p"},{"type":"image","alt":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","displaySize":"","headline":null,"caption":"Azitra Logo (PRNewsfoto/Azitra, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":199,"url":"https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ADn6KpXSrfB9stFJaBf9GA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/75baaaf4bd9c14c2c8baec6d5cdef4c5","width":400,"height":199}},"href":"https://mma.prnewswire.com/media/2555910/Azitra_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Q1 2025 and Recent Business Highlights","length":38,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced acceptance of poster detailing the Phase 1/2 clinical trial of the ATR-04 program in EGFR inhibitor ("EGFRi")-associated rash at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting","length":222,"tagName":"p"}]},{"val":[{"type":"text","content":"Entered into Purchase Agreement for up to $20 Million in Partnership with institutional investor Alumni Capital LP, to fund clinical pipeline","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced closing of two public offerings raising a total of $2.2M","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":429,"olType":false},{"type":"text","content":""The start of 2025 has been a vital period for Azitra as we build towards key milestones expected by mid-year for our first-in-class, precision, live biotherapeutic candidates designed for major undertreated dermatological diseases," said Francisco Salva, CEO of Azitra. "For ATR-12, our lead program targeting the rare, chronic and devastating Netherton syndrome, we expect to provide initial safety data from our Phase 1b trial in the first half of 2025 with topline results expected by year-end 2025. There are no approved treatments f...